FDA Brief

Warning letters Drugs

FDA warning letter to

Clean Cosmetics LLC

High riskIssued Jan 30, 2023Posted Feb 14, 2023Division of Pharmaceutical Quality Operations IV

FDA warned Clean Cosmetics LLC over manufacturing failures in OTC hand sanitizer, including ethanol contaminated with methanol.

What happened

FDA inspected Clean Cosmetics LLC in Moorpark, CA, from August 11 to 19, 2022, after a January 26, 2022 records request. FDA found the firm did not test incoming components for identity, released hand sanitizer made with ethanol containing unacceptable methanol, and did not perform microbial or impurity testing before release. FDA publicly notified consumers on August 3, 2022.

What FDA found

  1. The firm used incoming components without at least one identity test and did not validate supplier test reports (certificates of analysis).

    21 CFR 211.84(d)(1) and (2)
  2. The firm did not test each finished hand sanitizer batch for microbial contamination and impurities before release.

    21 CFR 211.165(a)
  3. The quality control unit lacked adequate procedures and authority for oversight, investigations, corrective actions, supplier qualification, cleaning, and water monitoring.

    21 CFR 211.22

What FDA wants

FDA tells Clean Cosmetics to respond in writing within 15 working days with corrective actions and supporting evidence. If it plans to resume drug manufacturing, it must have adequate corrective actions in place and notify FDA to schedule a meeting before resuming.

Who should pay attention

  • consumers who used or may use TrustRX hand sanitizer
  • retailers and distributors selling OTC hand sanitizer
  • contract manufacturers and brands that rely on supplier COAs for ethanol

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. World Perfumes Inc.

    World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.

    High risk
  2. RNA Bio/Pharma, Incorporated

    FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.

    High risk
  3. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  4. Ningbo Riway Industrial Co., Ltd.

    Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.

    High risk